As Aurora A–mediated phosphorylation of PKM2 at T45 plays a critical role in glycolytic modulation, biomass synthesis pathways, and tumor progression, blocking phosphorylation of PKM2 at T45 by Aurora A inhibitor could be a promising therapeutic strategy for lung cancers. This evidence concerns the gene PKM and neoplasm.